FDA awards record number of review designations to mRNA vaccines in 2023: GlobalData
Following FDA approval in August 2021, Pfizer’s Comirnaty became the first mRNA vaccine to enter the global market, followed by…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pfizer
M&A trends to watch out in pharma
Aditya Patni, Partner; Achint Kaur and Siddharth Marwah, Counsels at Khaitan & Co decode and decipher factors spurring…
Pfizer investigational gene therapy for DMD fails in Phase 3 study
The overall safety profile of fordadistrogene movaparvovec in the CIFFREO trial was manageable, with mostly mild to moderate…
PROTACs oncology market to hit $3.7 billion by 2030 despite lack of approved therapies: GlobalData
The PROTAC oncology market is projected to capture $3.7 billion by 2030 Proteolysis targeting chimeras (PROTACs) are a…
Pfizer, AstraZeneca to invest nearly $1 bn in France
Pfizer would invest $538.5 million in France to build up its research and development work in the country, while AstraZeneca…
Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028:…
GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…
Glenmark partners with Pfizer to launch Abrocitinib in India
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively
Fortifying Brand India Pharma
Lessons and insights on measures and approaches to drive innovation, quality and growth in India's pharma sector from industry…
USFDA approves SpringWorks Therapeutics’ non-cancerous tumor treatment
Shares of the company were up about 18 per cent after the bell
Penbraya approval sparks shift to pentavalent meningococcal vaccines in US: GlobalData
GSK is also in the process of developing a pentavalent vaccine, and positive Phase III data were announced earlier this year.…